Molecular and genetic insights into an infantile epileptic encephalopathy – CDKL5 disorder

doi:10.1007/s11515-016-1438-7

Front. Biol.

2017, Vol. 12

Issue (1) : 1-6 https://doi.org/10.1007/s11515-016-1438-7

MINI-REVIEW

Molecular and genetic insights into an infantile epileptic encephalopathy – CDKL5 disorder

Ailing Zhou¹,Song Han¹,Zhaolan Joe Zhou²(

)

¹. Jiaozhou People’s Hospital, Jiaozhou, Shangdong 266300, China
². Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

Download: PDF(105 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

BACKGROUND: The discovery that mutations in cyclin-dependent kinase-like 5 (CDKL5) gene are associated with infantile epileptic encephalopathy has stimulated world-wide research effort to understand the molecular and genetic basis of CDKL5 disorder. Given the large number of literature published thus far, this review aims to summarize current genetic studies, draw a consensus on proposed molecular functions, and point to gaps of knowledge in CDKL5 research.

METHODS: A systematic review process was conducted using the PubMed search engine focusing on CDKL5 studies in the recent ten years. We analyzed these publications and summarized the findings into four sections: genetic studies, CDKL5 expression patterns, molecular functions, and animal models. We also discussed challenges and future directions in each section.

RESULTS: On the clinical side, CDKL5 disorder is characterized by early onset epileptic seizures, intellectual disability, and stereotypical behaviors. On the research side, a series of molecular and genetic studies in human patients, cell cultures and animal models have established the causality of CDKL5 to the infantile epileptic encephalopathy, and pointed to a key role for CDKL5 in regulating neuronal function in the brain. Mouse models of CDKL5 disorder have also been developed, and notably, manifest behavioral phenotypes, mimicking numerous clinical symptoms of CDKL5 disorder and advancing CDKL5 research to the preclinical stage.

CONCLUSIONS: Given what we have learned thus far, future identification of robust, quantitative, and sensitive outcome measures would be the key in animal model studies, particularly in heterozygous females. In the meantime, molecular and cellular studies of CDKL5 should focus on mechanism-based investigation and aim to uncover druggable targets that offer the potential to rescue or ameliorate CDKL5 disorder-related phenotypes.

Keywords CDKL5 disorder childhood epilepsy intellectual disability mouse model outcome measure

Corresponding Author(s): Zhaolan Joe Zhou

Just Accepted Date: 26 December 2016 Online First Date: 23 January 2017 Issue Date: 28 February 2017

Cite this article:

Ailing Zhou,Song Han,Zhaolan Joe Zhou. Molecular and genetic insights into an infantile epileptic encephalopathy – CDKL5 disorder[J]. Front. Biol., 2017, 12(1): 1-6.

URL:

https://academic.hep.com.cn/fib/EN/10.1007/s11515-016-1438-7
https://academic.hep.com.cn/fib/EN/Y2017/V12/I1/1

1	Amendola E, Zhan Y, Mattucci C, Castroflorio E, Calcagno E, Fuchs C, Lonetti G, Silingardi D, Vyssotski A L, Farley D, Ciani E, Pizzorusso T, Giustetto M, Gross C T (2014). Mapping pathological phenotypes in a mouse model of CDKL5 disorder. PLoS One, 9(5): e91613–e12 https://doi.org/10.1371/journal.pone.0091613
2	Archer H L (2006). CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. J Med Genet, 43(9): 729–734 https://doi.org/10.1136/jmg.2006.041467
3	Bahi-Buisson N, Nectoux J, Rosas-Vargas H, Milh M, Boddaert N, Girard B, Cances C, Ville D, Afenjar A, Rio M, Heron D, N’Guyen Morel M A, Arzimanoglou A, Philippe C, Jonveaux P, Chelly J, Bienvenu T (2008). Key clinical features to identify girls with CDKL5 mutations. Brain, 131(10): 2647–2661 doi:10.1093/brain/awn197
4	Bahi-Buisson N, Villeneuve N, Caietta E, Jacquette A, Maurey H, Matthijs G, Van Esch H, Delahaye A, Moncla A, Milh M, Zufferey F, Diebold B, Bienvenu T (2012). Recurrent mutations in the CDKL5 gene: Genotype-phenotype relationships. Am J Med Genet, 158A(7): 1612–1619 https://doi.org/10.1002/ajmg.a.35401
5	Chahrour M, Zoghbi H Y (2007). The story of Rett syndrome: From clinic to neurobiology. Neuron, 56(3): 422–437 https://doi.org/10.1016/j.neuron.2007.10.001
6	Chen Q, Zhu Y C, Yu J, Miao S, Zheng J, Xu L, Zhou Y, Li D, Zhang C, Tao J, Xiong Z Q (2010). CDKL5, a Protein associated with rett syndrome, regulates neuronal morphogenesis via Rac1 signaling. J Neurosci, 30(38): 12777–12786 https://doi.org/10.1523/JNEUROSCI.1102-10.2010
7	Crino P B (2011). mTOR: A pathogenic signaling pathway in developmental brain malformations. Trends Mol Med, 17(12): 734–742 https://doi.org/10.1016/j.molmed.2011.07.008
8	Della Sala G, Putignano E, Chelini G, Melani R, Calcagno E, Michele Ratto G, Amendola E, Gross C T, Giustetto M, Pizzorusso T (2016). Dendritic spine instability in a mouse model of CDKL5 disorder is rescued by insulin-like growth factor 1. Biol Psychiatry, 80(4): 302–311 https://doi.org/10.1016/j.biopsych.2015.08.028
9	Diebold B, Delépine C, Gataullina S, Delahaye A, Nectoux J, Bienvenu T (2014). Mutations in the C-terminus of CDKL5: proceed with caution. Eur J Hum Genet, 22(2): 270–272 https://doi.org/10.1038/ejhg.2013.133
10	Fehr S, Downs J, Ho G, de Klerk N, Forbes D, Christodoulou J, Williams S, Leonard H (2016). Functional abilities in children and adults with the CDKL5 disorder. Am J Med Genet, 170(11): 1–10
11	Fehr S, Wilson M, Downs J, Williams S, Murgia A, Sartori S, Vecchi M, Ho G, Polli R, Psoni S, Bao X, de Klerk N, Leonard H, Christodoulou J (2012). The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet, 21: 266–273
12	Fuchs C, Rimondini R, Viggiano R, Trazzi S, De Franceschi M, Bartesaghi R, Ciani E (2015). Inhibition of GSK3b rescues hippocampal development and learning in a mouse model of CDKL5 disorder. Neurobiol Dis, 82: 298–310 https://doi.org/10.1016/j.nbd.2015.06.018
13	Fuchs C, Trazzi S, Torricella R, Viggiano R, De Franceschi M, Amendola E, Gross C, Calzà L, Bartesaghi R, Ciani E (2014). Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AK/GSK-3b signaling. Neurobiol Dis, 70: 53–68 https://doi.org/10.1016/j.nbd.2014.06.006
14	Hanefeld F (1985). The clinical pattern of the rett syndrome. Brain Dev, 7(3): 320–325 https://doi.org/10.1016/S0387-7604(85)80037-1
15	Hector R D, Dando O, Landsberger N, Kilstrup-Nielsen C, Kind P C, Bailey M E, Cobb S R (2016). Characterisation of CDKL5 transcript isoforms in human and mouse. PLoS One. 11(6):e0157758. https://doi.org/10.1371/journal.pone.0157758
16	Kalscheuer V M, Tao J, Donnelly A, Hollway G, Schwinger E, Kübart S, Menzel C, Hoeltzenbein M, Tommerup N, Eyre H, Harbord M, Haan E, Sutherland G R, Ropers H H, Gécz J (2003). Disruption of the serine/threonine kinase 9 gene causes severe X–linked infantile spasms and mental retardation. Am J Hum Genet, 72(6): 1401–1411 https://doi.org/10.1086/375538
17	Kameshita I, Sekiguchi M, Hamasaki D, Sugiyama Y, Hatano N, Suetake I, Tajima S, Sueyoshi N (2008). Cyclin-dependent kinase-like 5 binds and phosphorylates DNA methyltransferase 1. Biochem Biophys Res Commun, 377(4): 1162–1167 https://doi.org/10.1016/j.bbrc.2008.10.113
18	Lin C, Franco B, Rosner M R (2005). CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders. Hum Mol Genet, 14(24): 3775–3786 https://doi.org/10.1093/hmg/ddi391
19	Mari F, Azimonti S, Bertani I, Bolognese F, Colombo E, Caselli R, Scala E, Longo I, Grosso S, Pescucci C, Ariani F, Hayek G, Balestri P, Bergo A, Badaracco G, Zappella M, Broccoli V, Renieri A, Kilstrup-Nielsen C, Landsberger N (2005). CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet, 14(14): 1935–1946 https://doi.org/10.1093/hmg/ddi198
20	Mastrangelo M, Leuzzi V (2012). Genes of early-onset epileptic encephalopathies: from genotype to phenotype. Pediatr Neurol, 46(1): 24–31 https://doi.org/10.1016/j.pediatrneurol.2011.11.003
21	Montini E, Andolfi G, Caruso A, Buchner G, Walpole S M, Mariani M, Consalez G, Trump D, Ballabio A, Franco B (1998). Identification and characterization of a novel serine-threonine kinase gene from the Xp22 region. Genomics, 51(3): 427–433 https://doi.org/10.1006/geno.1998.5391
22	Nawaz M S, Giarda E, Bedogni F, La Montanara P, Ricciardi S, Ciceri D, Alberio T, Landsberger N, Rusconi L, Kilstrup-Nielsen C (2016). CDKL5 and Shootin1 Interact and Concur in Regulating Neuronal Polarization. PLoS One, 11(2): e0148634 https://doi.org/10.1371/journal.pone.0148634
23	Nemos C, Lambert L, Giuliano F, Doray B, Roubertie A, Goldenberg A, Delobel B, Layet V, N’guyen M A, Saunier A, Verneau F, Jonveaux P, Philippe C (2009). Mutational spectrum of CDKL5in early-onset encephalopathies: a study of a large collection of French patients and review of the literature. Clin Genet, 76(4): 357–371 https://doi.org/10.1111/j.1399-0004.2009.01194.x
24	Ricciardi S, Kilstrup-Nielsen C, Bienvenu T, Jacquette A, Landsberger N, Broccoli V (2009). CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery. Hum Mol Genet, 18(23): 4590–4602 https://doi.org/10.1093/hmg/ddp426
25	Ricciardi S, Ungaro F, Hambrock M, Rademacher N, Stefanelli G, Brambilla D, Sessa A, Magagnotti C, Bachi A, Giarda E, Verpelli C, Kilstrup-Nielsen C, Sala C, Kalscheuer V M, Broccoli V (2012). CDKL5 ensures excitatory synapse stability by reinforcing NGL-1–PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat Cell Biol, 14(9): 911–923 https://doi.org/10.1038/ncb2566
26	Rusconi L, Kilstrup-Nielsen C, Landsberger N (2011). Extrasynaptic N-methyl-D-aspartate (NMDA) receptor stimulation induces cytoplasmic translocation of the CDKL5 kinase and its proteasomal degradation. J Biol Chem, 286(42): 36550–36558 https://doi.org/10.1074/jbc.M111.235630
27	Rusconi L, Salvatoni L, Giudici L, Bertani I, Kilstrup-Nielsen C, Broccoli V, Landsberger N (2008). CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail. J Biol Chem, 283(44): 30101–30111 https://doi.org/10.1074/jbc.M804613200
28	Sekiguchi M, Katayama S, Hatano N, Shigeri Y, Sueyoshi N, Kameshita I (2013). Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder. Arch Biochem Biophys, 535(2): 257–267 https://doi.org/10.1016/j.abb.2013.04.012
29	Tao J, Van Esch H, Hagedorn-Greiwe M, Hoffmann K, Moser B, Raynaud M, Sperner J, Fryns J P, Schwinger E, Gécz J, Ropers H H, Kalscheuer V M (2004). Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. Am J Hum Genet, 75(6): 1149–1154 https://doi.org/10.1086/426460
30	Wang I T, Allen M, Goffin D, Zhu X, Fairless A H, Brodkin E S, Siegel S J, Marsh E D, Blendy J A, Zhou Z (2012). Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc Natl Acad Sci USA, 109(52): 21516–21521 https://doi.org/10.1073/pnas.1216988110
31	Weaving L S, Christodoulou J, Williamson S L, Friend K L, McKenzie O L D, Archer H, Evans J, Clarke A, Pelka G J, Tam P P L, Watson C, Lahooti H, Ellaway C J, Bennetts B, Leonard H, Gécz J (2004). Mutations of CDKL5 Cause a Severe Neurodevelopmental Disorder with Infantile Spasms and Mental Retardation. Am J Hum Genet, 75(6): 1079–1093 https://doi.org/10.1086/426462
32	Zhu Y C, Li D, Wang L, Lu B, Zheng J, Zhao S L, Zeng R, Xiong Z Q (2013). Palmitoylation-dependent CDKL5-PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development. Proc Natl Acad Sci USA, 110(22): 9118–9123 https://doi.org/10.1073/pnas.1300003110

[1]	Fatih Semerci,Mirjana Maletic-Savatic. Transgenic mouse models for studying adult neurogenesis[J]. Front. Biol., 2016, 11(3): 151-167.
[2]	Jeffrey P. CANTLE, Xiao-Hong LU, Xiaofeng GU, X. William YANG. Cellular and molecular mechanisms implicated in pathogenesis of selective neurodegeneration in Huntington’s disease[J]. Front Biol, 2012, 7(5): 459-476.

Viewed

Full text

Abstract

Cited

Shared

Discussed